

FORMA Therapeutics and Experimental Therapeutics Centre of Singapore Collaborate to Develop Therapeutics Against a Broad Range of Novel Targets

Cambridge, MA. March 15, 2009 –FORMA Therapeutics and the Experimental Therapeutics Centre of Singapore (ETC) announced today a collaboration agreement to leverage FORMA's transformative chemistry platform to discover novel compounds for further development by ETC. ETC is funded by the Agency for Science, Technology & Research (A*STAR) of Singapore, which is committed to fostering world-class scientific research and talent for a vibrant, knowledge-based Singapore. Financial terms were not disclosed.

“Working collaboratively with ETC will allow us to demonstrate the power of FORMA's transformative chemistry platform across a broad range of targets pursued by ETC,” said Steven Tregay, CEO of FORMA. “We share a commitment to advancing early-stage science and translating those discoveries into practical clinical applications. This collaboration is therefore mutually beneficial, potentially bolstering Singapore's biomedical pipeline of the future, while also further validating the productivity and efficiency of FORMA's proprietary drug discovery technologies in identifying new, promising compounds.”

Professor Sir David Lane, Chief Executive Officer of ETC, added, “Many exciting scientific discoveries involve targets that have been historically intractable to traditional drug discovery approaches, so we are excited to be collaborating with FORMA to access their expertise in Diversity Orientated Synthesis to address these challenging targets. We hope these efforts may potentially result in new drug leads that ETC can then incubate and further develop into promising human therapeutics.”

“We are pleased that FORMA is able to leverage on Singapore's well established biomedical R&D capabilities and infrastructure to further grow shareholder value through Singapore” commented Swee-Yeok Chu, CEO, Bio*One Capital of EDB Investments. “FORMA's activities and presence here will add to the vibrancy of the local biomedical sciences research community” she said.

About FORMA

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. Capitalizing on the targets and pathways validated by the Cancer Genome Atlas Project and other related efforts, FORMA is developing a new generation of cancer therapies aimed at previously elusive drug targets. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing. www.formatherapeutics.com

About ETC

The Experimental Therapeutics Centre's (ETC) mission is to mine the gap between basic and applied biomedical research. Academic institutions are playing an increasingly important role in translating scientific discoveries into practical applications – from engaging in early stage drug discovery and development, to developing innovative research tools for clinical analysis, as well as setting up public-private partnerships to facilitate the advancement of drug candidates. ETC was conceived to contribute to this exciting process of translational work. ETC will augment Singapore's capabilities and resources in this spectrum of the drug discovery process.

About Bio*One Capital

*EDB Investments' subsidiary Bio*One Capital is a leading, biomedical sciences dedicated investment management company in Asia with a global presence. Investments are focused on promising and innovative international biomedical companies where Bio*One Capital can play a value-adding role in bridging and supporting growth strategies in Asia through Singapore. Bio*One Capital oversees a portfolio of over 50 companies in US, Europe, Singapore and Asia. For more information, please visit www.bio1capital.com.*

Contact:

FORMA Therapeutics
Steven Tregay, CEO
(617) 679-1970

Media Contact:
Douglas MacDougall – 781-235-3060
MacDougall Biomedical Communications

####